The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...

Dexcom has won FDA clearance of the Smart Basal, a CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy. The clearance ...

Weeks after launching its first open call for diabetes advocates, Dexcom is spotlighting the resulting group of 16 people in a new awareness campaign. The project kicked off Friday, World Diabetes Day ...

Dexcom CGM systems provide automatic blood glucose updates every five minutes. FreeStyle Libre sensors can last up to 15 days and no longer need frequent scanning for updates. Both Dexcom and ...

The Federal Circuit upheld an administrative tribunal’s decision to nix six claims from a DexCom Inc. patent covering implantable sensors used to monitor patients’ blood glucose levels. DexCom sued ...

People with diabetes can use continuous glucose monitors (CGMs) to make tracking their blood sugar levels easier. Instead of drawing blood multiple times per day, a person continuously wears a sensor ...

In March 2024, the FDA approved the first over-the-counter continuous glucose monitors (CGMs), marking a quiet but significant shift in how we can track and understand our health. Devices like ...

DexCom has a well-established record of introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, DexCom has captured an impressive slice of ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship G7 sensor. The new system, which boosts wear time up from the previous ...

A warning letter posted Tuesday by the Food and Drug Administration revealed quality control issues with Dexcom’s continuous glucose monitors. The FDA raised concerns with a design change to a ...